Worth a closer look
- Open-market purchase with their own money (Form 4 code P), not a grant or option exercise.
Reasons for caution
- Other insiders sold $492M in the same 90 days, more than was bought (0% of it pre-planned).
- Bought by a 10% owner or investment firm, whose reasons often differ from an executive's.
- Small next to what they already own (holding up 0.2%).
- Similar past buys beat the S&P 500 only 43% of the time (670 cases); the typical one trailed it by 2.9%.
What happened after this filing
Insider Twins: past buys with the same traits
1 insider buying · no CEO or CFO · $1M+ · stock up over 3 months
GME Dec 21, 2020 +1183.4% vs S&PAEVA Mar 31, 2025 +410.2% vs S&PHYMC Oct 16, 2025 +282.5% vs S&PFULC Jan 24, 2023 -82.8% vs S&PFULC Jan 6, 2023 -80.3% vs S&PFWRD Feb 17, 2026 -77.3% vs S&PWhat we couldn't check
- Why they traded. Filings don't say, and we don't guess.
- Company news after the filing, and any private terms.
Nippon Life Insurance Co (a 10% owner) bought $8.8M of CRBG at about $35.50 on Oct 29, 2026, reported to the SEC on Nov 2, 2026. Buys like this beat the S&P 500 43% of the time since 2020, against 46% for all insider buys. We found 1 point that make it worth a closer look and 4 reasons for caution. History, not a prediction.
Following. We'll keep this page updated; see everything you follow. Want an email when the 30 and 90-day results land? Use the CRBG alerts below.
Get this week's insider report
The week's biggest insider buys, every new cluster buy and the stocks to watch, in one printable PDF. Plus the free Monday email.
Check your inbox to confirm, so you get next week's report too.
Written by fixed rules from SEC filings and our measured history, not by an AI model. Public data only. History, not a prediction, and not investment advice.